Multidimensional Effectiveness of Botulinum Toxin in Neuropathic Pain: A Systematic Review of Randomized Clinical Trials

Lorenzo Lippi, Alessandro de Sire, Arianna Folli, Francesco D'Abrosca, Elisa Grana, Alessio Baricich, Stefano Carda, Marco Invernizzi, Lorenzo Lippi, Alessandro de Sire, Arianna Folli, Francesco D'Abrosca, Elisa Grana, Alessio Baricich, Stefano Carda, Marco Invernizzi

Abstract

Although botulinum toxin (BoNT) has been suggested as a treatment to counter neuropathic pain, no previous systematic reviews investigated the multidimensional effects of BoNT on pain relief and Health-Related Quality of Life (HR-QoL). The aim of this systematic review is to summarize the current evidence on the effectiveness of BoNT treatment for neuropathic pain, and to characterize its multidimensional effectiveness in order to guide physicians in clinical practice. Five databases were systematically searched up to 4 April 2022, to identify randomized controlled trials satisfying the following criteria: adults suffering from neuropathic pain, BoNT administration, any comparator, multidimensional assessment of pain as primary outcome, HR-QoL, physical function, anxiety and depression, and sleep quality as secondary outcomes. Twelve studies were included. The multidimensional pain scales used were short-form McGill Pain Questionnaire, Neuropathic pain scale, Neuropathic Pain Symptom Inventory, International SCI Pain Basic Data Set, West Haven-Yale Multidimensional Pain Inventory, Brief Pain Inventory, and Douleur Neuropathique 4. These scales highlighted the positive effects of BoNT administration. According to the Jadad scale, all the RCTs included were high-quality studies. BoNT administration might be effectively introduced in the comprehensive management of neuropathic pain. Further research should focus on optimal and cost-effective therapeutic protocols.

Keywords: botulinum toxin (BoNT); neuropathic pain; pain management; quality of life; rehabilitation.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA 2020 flow chart.
Figure 2
Figure 2
Risk of bias summary of the included studies.

References

    1. Scholz J., Finnerup N.B., Attal N., Aziz Q., Baron R., Bennett M.I., Benoliel R., Cohen M., Cruccu G., Davis K.D., et al. The IASP classification of chronic pain for ICD-11: Chronic neuropathic pain. Pain. 2019;160:53–59. doi: 10.1097/j.pain.0000000000001365.
    1. Doth A.H., Hansson P.T., Jensen M.P., Taylor R.S. The burden of neuropathic pain: A systematic review and meta-analysis of health utilities. Pain. 2010;149:338–344. doi: 10.1016/j.pain.2010.02.034.
    1. Bernetti A., Agostini F., de Sire A., Mangone M., Tognolo L., Di Cesare A., Ruiu P., Paolucci T., Invernizzi M., Paoloni M. Neuropathic Pain and Rehabilitation: A Systematic Review of International Guidelines. Diagnostics. 2021;11:74. doi: 10.3390/diagnostics11010074.
    1. Langley P.C., Van Litsenburg C., Cappelleri J.C., Carroll D. The burden associated with neuropathic pain in Western Europe. J. Med. Econ. 2013;16:85–95. doi: 10.3111/13696998.2012.729548.
    1. Colloca L., Ludman T., Bouhassira D., Baron R., Dickenson A.H., Yarnitsky D., Freeman R., Truini A., Attal N., Finnerup N.B., et al. Neuropathic pain. Nat. Rev. Dis. Primers. 2017;3:17002. doi: 10.1038/nrdp.2017.2.
    1. Van Hecke O., Austin S.K., Khan R.A., Smith B.H., Torrance N. Neuropathic pain in the general population: A systematic review of epidemiological studies. Pain. 2014;155:654–662. doi: 10.1016/j.pain.2013.11.013.
    1. Deng Y., Luo L., Hu Y., Fang K., Liu J. Clinical practice guidelines for the management of neuropathic pain: A systematic review. BMC Anesth. 2016;16:12. doi: 10.1186/s12871-015-0150-5.
    1. Bates D., Schultheis B.C., Hanes M.C., Jolly S.M., Chakravarthy K.V., Deer T.R., Levy R.M., Hunter C.W. A Comprehensive Algorithm for Management of Neuropathic Pain. Pain Med. 2019;20:S2–S12. doi: 10.1093/pm/pnz075.
    1. Baron R., Binder A., Wasner G. Neuropathic pain: Diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9:807–819. doi: 10.1016/S1474-4422(10)70143-5.
    1. Braz J., Solorzano C., Wang X., Basbaum A.I. Transmitting pain and itch messages: A contemporary view of the spinal cord circuits that generate gate control. Neuron. 2014;82:522–536. doi: 10.1016/j.neuron.2014.01.018.
    1. Tsuda M., Koga K., Chen T., Zhuo M. Neuronal and microglial mechanisms for neuropathic pain in the spinal dorsal horn and anterior cingulate cortex. J. Neurochem. 2017;141:486–498. doi: 10.1111/jnc.14001.
    1. Nelson T.S., Fu W., Donahue R.R., Corder G.F., Hokfelt T., Wiley R.G., Taylor B.K. Facilitation of neuropathic pain by the NPY Y1 receptor-expressing subpopulation of excitatory interneurons in the dorsal horn. Sci. Rep. 2019;9:7248. doi: 10.1038/s41598-019-43493-z.
    1. Papuc E., Rejdak K. The role of neurostimulation in the treatment of neuropathic pain. Ann. Agric. Environ. Med. 2013;1:14–17.
    1. Wu G., Ringkamp M., Hartke T.V., Murinson B.B., Campbell J.N., Griffin J.W., Meyer R.A. Early onset of spontaneous activity in uninjured C-fiber nociceptors after injury to neighboring nerve fibers. J. Neurosci. 2001;21:RC140. doi: 10.1523/JNEUROSCI.21-08-j0002.2001.
    1. Caterina M.J., Julius D. The vanilloid receptor: A molecular gateway to the pain pathway. Ann. Rev. Neurosci. 2001;24:487–517. doi: 10.1146/annurev.neuro.24.1.487.
    1. Serra J., Sola R., Quiles C., Casanova-Molla J., Pascual V., Bostock H., Valls-Sole J. C-nociceptors sensitized to cold in a patient with small-fiber neuropathy and cold allodynia. Pain. 2009;147:46–53. doi: 10.1016/j.pain.2009.07.028.
    1. Wasner G., Schattschneider J., Binder A., Baron R. Topical menthol—A human model for cold pain by activation and sensitization of C nociceptors. Brain. 2004;127:1159–1171. doi: 10.1093/brain/awh134.
    1. Chaparro L.E., Wiffen P.J., Moore R.A., Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst. Rev. 2012;2020:CD008943. doi: 10.1002/14651858.CD008943.pub2.
    1. Smith E.S.J. Advances in understanding nociception and neuropathic pain. J. Neurol. 2018;265:231–238. doi: 10.1007/s00415-017-8641-6.
    1. De Sire A., Ammendolia A., Lippi L., Farì G., Cisari C., Invernizzi M. Percutaneous Electrical Nerve Stimulation (PENS) as a Rehabilitation Approach for Reducing Mixed Chronic Pain in Patients with Musculoskeletal Disorders. Appl. Sci. 2021;11:4257. doi: 10.3390/app11094257.
    1. De Sire A., Lippi L., Curci C., Calafiore D., Cisari C., Ammendolia A., Invernizzi M. Effectiveness of Combined Treatment Using Physical Exercise and Ultrasound-Guided Radiofrequency Ablation of Genicular Nerves in Patients with Knee Osteoarthritis. Appl. Sci. 2021;11:4338. doi: 10.3390/app11104338.
    1. Harden N., Cohen M. Unmet Needs in the Management of Neuropathic Pain. J. Pain Symptom Manag. 2003;25:S12–S17. doi: 10.1016/S0885-3924(03)00065-4.
    1. Intiso D., Basciani M., Santamato A., Intiso M., Di Rienzo F. Botulinum Toxin Type A for the Treatment of Neuropathic Pain in Neuro-Rehabilitation. Toxins. 2015;7:2454–2480. doi: 10.3390/toxins7072454.
    1. Fishman L.M., Anderson C., Rosner B. BOTOX and physical therapy in the treatment of piriformis syndrome. Am. J. Phys. Med. Rehabil. 2002;81:936–942. doi: 10.1097/00002060-200212000-00009.
    1. Baricich A., Picelli A., Carda S., Smania N., Cisari C., Santamato A., de Sire A., Invernizzi M. Electrical stimulation of antagonist muscles after botulinum toxin type A for post-stroke spastic equinus foot. A randomized single-blind pilot study. Ann. Phys. Rehabil. Med. 2019;62:214–219. doi: 10.1016/j.rehab.2019.06.002.
    1. Attal N., de Andrade D.C., Adam F., Ranoux D., Teixeira M.J., Galhardoni R., Raicher I., Uceyler N., Sommer C., Bouhassira D. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2016;15:555–565. doi: 10.1016/S1474-4422(16)00017-X.
    1. Foster L., Clapp L., Erickson M., Jabbari B. Botulinum toxin A and chronic low back pain: A randomized, double-blind study. Neurology. 2001;56:1290–1293. doi: 10.1212/WNL.56.10.1290.
    1. Park H.J., Lee Y., Lee J., Park C., Moon D.E. The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can. J. Anaesth. 2006;53:470–477. doi: 10.1007/BF03022619.
    1. Finnerup N.B., Attal N., Haroutounian S., McNicol E., Baron R., Dworkin R.H., Gilron I., Haanpaa M., Hansson P., Jensen T.S., et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol. 2015;14:162–173. doi: 10.1016/S1474-4422(14)70251-0.
    1. Moisset X., Bouhassira D., Avez Couturier J., Alchaar H., Conradi S., Delmotte M.H., Lanteri-Minet M., Lefaucheur J.P., Mick G., Piano V., et al. Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. Rev. Neurol. 2020;176:325–352. doi: 10.1016/j.neurol.2020.01.361.
    1. Morra M.E., Elgebaly A., Elmaraezy A., Khalil A.M., Altibi A.M., Vu T.L., Mostafa M.R., Huy N.T., Hirayama K. Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: A systematic review and meta-analysis of randomized controlled trials. J. Headache Pain. 2016;17:63. doi: 10.1186/s10194-016-0651-8.
    1. Do T.M., Unis G.D., Kattar N., Ananth A., McCoul E.D. Neuromodulators for Atypical Facial Pain and Neuralgias: A Systematic Review and Meta-Analysis. Laryngoscope. 2021;131:1235–1253. doi: 10.1002/lary.29162.
    1. Li X.L., Zeng X., Zeng S., He H.P., Zeng Z., Peng L.L., Chen L.G. Botulinum toxin A treatment for post-herpetic neuralgia: A systematic review and meta-analysis. Exp. Med. 2020;19:1058–1064. doi: 10.3892/etm.2019.8301.
    1. Battista S., Buzzatti L., Gandolfi M., Finocchi C., Falsiroli Maistrello L., Viceconti A., Giardulli B., Testa M. The Use of Botulinum Toxin A as an Adjunctive Therapy in the Management of Chronic Musculoskeletal Pain: A Systematic Review with Meta-Analysis. Toxins. 2021;13:640. doi: 10.3390/toxins13090640.
    1. Dawson A., Dawson J., Ernberg M. The effect of botulinum toxin A on patients with persistent idiopathic dentoalveolar pain—A systematic review. J. Oral Rehabil. 2020;47:1184–1191. doi: 10.1111/joor.13053.
    1. Apalla Z., Sotiriou E., Lallas A., Lazaridou E., Ioannides D. Botulinum toxin A in postherpetic neuralgia: A parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin. J. Pain. 2013;29:857–864. doi: 10.1097/AJP.0b013e31827a72d2.
    1. Chun A., Levy I., Yang A., Delgado A., Tsai C.Y., Leung E., Taylor K., Kolakowsky-Hayner S., Huang V., Escalon M., et al. Treatment of at-level spinal cord injury pain with botulinum toxin A. Spinal Cord Ser. Cases. 2019;5:77. doi: 10.1038/s41394-019-0221-9.
    1. Finlayson H.C., O’Connor R.J., Brasher P.M.A., Travlos A. Botulinum toxin injection for management of thoracic outlet syndrome: A double-blind, randomized, controlled trial. Pain. 2011;152:2023–2028. doi: 10.1016/j.pain.2011.04.027.
    1. Ghasemi M., Ansari M., Basiri K., Shaigannejad V. The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy. J. Res. Med. Sci. 2014;19:106–111.
    1. Han Z.A., Song D.H., Oh H.M., Chung M.E. Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. Ann. Neurol. 2016;79:569–578. doi: 10.1002/ana.24605.
    1. Ranoux D., Attal N., Morain F., Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann. Neurol. 2008;64:274–283. doi: 10.1002/ana.21427.
    1. Salehi H., Moussaei M., Kamiab Z., Vakilian A. The effects of botulinum toxin type A injection on pain symptoms, quality of life, and sleep quality of patients with diabetic neuropathy: A randomized double-blind clinical trial. Iran. J. Neurol. 2019;18:99–107. doi: 10.18502/ijnl.v18i3.1632.
    1. Taheri M., Sedaghat M., Solhpour A., Rostami P., Lima B.S. The Effect of Intradermal Botulinum Toxin a injections on painful diabetic polyneuropathy. Diabetes Metab. Syndr. Clin. Res. Rev. 2020;14:1823–1828. doi: 10.1016/j.dsx.2020.09.019.
    1. Xiao L., Mackey S., Hui H., Xong D., Zhang Q., Zhang D. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med. 2010;11:1827–1833. doi: 10.1111/j.1526-4637.2010.01003.x.
    1. Yuan R.Y., Sheu J.J., Yu J.M., Chen W.T., Tseng I.J., Chang H.H., Hu C.J. Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial. Neurology. 2009;72:1473–1478. doi: 10.1212/.
    1. Breuer B., Sperber K., Wallenstein S., Kiprovski K., Calapa A., Snow B., Pappagallo M. Clinically significant placebo analgesic response in a pilot trial of botulinum B in patients with hand pain and carpal tunnel syndrome. Pain Med. 2006;7:16–24. doi: 10.1111/j.1526-4637.2006.00084.x.
    1. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., McQuay H.J. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control. Clin. Trials. 1996;17:1–12. doi: 10.1016/0197-2456(95)00134-4.
    1. Sterne J.A.C., Savovic J., Page M.J., Elbers R.G., Blencowe N.S., Boutron I., Cates C.J., Cheng H.Y., Corbett M.S., Eldridge S.M., et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898.
    1. Egeo G., Fofi L., Barbanti P. Botulinum Neurotoxin for the Treatment of Neuropathic Pain. Front. Neurol. 2020;11:716. doi: 10.3389/fneur.2020.00716.
    1. Oh H.M., Chung M.E. Botulinum Toxin for Neuropathic Pain: A Review of the Literature. Toxins. 2015;7:3127–3154. doi: 10.3390/toxins7083127.
    1. Park J., Chung M.E. Botulinum Toxin for Central Neuropathic Pain. Toxins. 2018;10:224. doi: 10.3390/toxins10060224.
    1. Park J., Park H.J. Botulinum Toxin for the Treatment of Neuropathic Pain. Toxins. 2017;9:260. doi: 10.3390/toxins9090260.
    1. Wei J., Zhu X., Yang G., Shen J., Xie P., Zuo X., Xia L., Han Q., Zhao Y. The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials. Brain Behav. 2019;9:e01409. doi: 10.1002/brb3.1409.
    1. Lakra C., Cohen H. A clinical review of the use of Botulinum Toxin type A in managing central neuropathic pain in patients with spinal cord injury. J. Spinal Cord Med. 2020;2:1–5. doi: 10.1080/10790268.2020.1848278.
    1. Ahmed S., Subramaniam S., Sidhu K., Khattab S., Singh D., Babineau J., Kumbhare D.A. Effect of Local Anesthetic Versus Botulinum Toxin-A Injections for Myofascial Pain Disorders: A Systematic Review and Meta-Analysis. Clin. J. Pain. 2019;35:353–367. doi: 10.1097/AJP.0000000000000681.
    1. Forstenpointner J., Rice A.S.C., Finnerup N.B., Baron R. Up-date on Clinical Management of Postherpetic Neuralgia and Mechanism-Based Treatment: New Options in Therapy. J. Infect. Dis. 2018;218:S120–S126. doi: 10.1093/infdis/jiy381.
    1. Hary V., Schitter S., Martinez V. Efficacy and safety of botulinum A toxin for the treatment of chronic peripheral neuropathic pain: A systematic review of randomized controlled trials and meta-analysis. Eur. J. Pain. 2022;26:980–990. doi: 10.1002/ejp.1941.
    1. Van Boekel R.L.M., Vissers K.C.P., van der Sande R., Bronkhorst E., Lerou J.G.C., Steegers M.A.H. Moving beyond pain scores: Multidimensional pain assessment is essential for adequate pain management after surgery. PLoS ONE. 2017;12:e0177345. doi: 10.1371/journal.pone.0177345.
    1. Teasell R., Foley N., Pereira S., Sequeira K., Miller T. Evidence to practice: Botulinum toxin in the treatment of spasticity post stroke. Top. Stroke Rehabil. 2012;19:115–121. doi: 10.1310/tsr1902-115.
    1. Baricich A., Picelli A., Santamato A., Carda S., de Sire A., Smania N., Cisari C., Invernizzi M. Safety Profile of High-Dose Botulinum Toxin Type A in Post-Stroke Spasticity Treatment. Clin. Drug Investig. 2018;38:991–1000. doi: 10.1007/s40261-018-0701-x.
    1. Hernandez Herrero D., Miangolarra Page J.C. Descriptive analysis of the annual cost of treating spasticity with different types of botulinum toxin A. Neurologia. 2019. in press .
    1. Smith B.H., Hebert H.L., Veluchamy A. Neuropathic pain in the community: Prevalence, impact, and risk factors. Pain. 2020;161((Suppl. 1)):S127–S137. doi: 10.1097/j.pain.0000000000001824.
    1. Wang C., Zhang Q., Wang R., Xu L. Botulinum Toxin Type A for Diabetic Peripheral Neuropathy Pain: A Systematic Review and Meta-Analysis. J. Pain Res. 2021;14:3855–3863. doi: 10.2147/JPR.S340390.
    1. Fitzmaurice B.C., Rayen A.T.A. Treatments for neuropathic pain: Up-to-date evidence and recommendations. BJA Educ. 2018;18:277–283. doi: 10.1016/j.bjae.2018.06.002.
    1. Rhon D.I., Fritz J.M., Greenlee T.A., Dry K.E., Mayhew R.J., Laugesen M.C., Dragusin E., Teyhen D.S. Move to health-a holistic approach to the management of chronic low back pain: An intervention and implementation protocol developed for a pragmatic clinical trial. J. Transl. Med. 2021;19:357. doi: 10.1186/s12967-021-03013-y.
    1. Sdrulla A., Chen G. Minimally invasive procedures for neuropathic pain. Pain Manag. 2016;2:6:103-9. doi: 10.2217/pmt.15.61.
    1. Szok D., Tajti J., Nyari A., Vecsei L. Therapeutic Approaches for Peripheral and Central Neuropathic Pain. Behav. Neurol. 2019;2019:8685954. doi: 10.1155/2019/8685954.
    1. Varshney V., Osborn J., Chaturvedi R., Shah V., Chakravarthy K. Advances in the interventional management of neuropathic pain. Ann. Transl. Med. 2021;9:187. doi: 10.21037/atm-20-6190.
    1. De Sire A., Moggio L., Demeco A., Fortunato F., Spano R., Aiello V., Marotta N., Ammendolia A. Efficacy of rehabilitative techniques in reducing hemiplegic shoulder pain in stroke: Systematic review and meta-analysis. Ann. Phys. Rehabil. Med. 2021;65:101602. doi: 10.1016/j.rehab.2021.101602.
    1. Cavalli E., Mammana S., Nicoletti F., Bramanti P., Mazzon E. The neuropathic pain: An overview of the current treatment and future therapeutic approaches. Int. J. Immunopathol. Pharm. 2019;33:2058738419838383. doi: 10.1177/2058738419838383.
    1. Petrosino S., Schiano Moriello A. Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries-A Systematic Review. Int. J. Mol. Sci. 2020;21:9526. doi: 10.3390/ijms21249526.
    1. Rowin J. Integrative neuromuscular medicine: Neuropathy and neuropathic pain: Consider the alternatives. Muscle Nerve. 2019;60:124–136. doi: 10.1002/mus.26510.
    1. Leitzelar B.N., Koltyn K.F. Exercise and Neuropathic Pain: A General Overview of Preclinical and Clinical Research. Sports Med. Open. 2021;7:21. doi: 10.1186/s40798-021-00307-9.
    1. Andersen Hammond E., Pitz M., Shay B. Neuropathic Pain in Taxane-Induced Peripheral Neuropathy: Evidence for Exercise in Treatment. Neurorehabil. Neural. Repair. 2019;33:792–799. doi: 10.1177/1545968319860486.
    1. Mokhtari T., Ren Q., Li N., Wang F., Bi Y., Hu L. Transcutaneous Electrical Nerve Stimulation in Relieving Neuropathic Pain: Basic Mechanisms and Clinical Applications. Curr. Pain Headache Rep. 2020;24:14. doi: 10.1007/s11916-020-0846-1.
    1. Domoto R., Sekiguchi F., Tsubota M., Kawabata A. Macrophage as a Peripheral Pain Regulator. Cells. 2021;10:1881. doi: 10.3390/cells10081881.
    1. Matak I., Bolcskei K., Bach-Rojecky L., Helyes Z. Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins. 2019;11:459. doi: 10.3390/toxins11080459.
    1. Lai J., Hunter J.C., Porreca F. The role of voltage-gated sodium channels in neuropathic pain. Curr. Opin. Neurobiol. 2003;13:291–297. doi: 10.1016/S0959-4388(03)00074-6.
    1. Black J.A., Nikolajsen L., Kroner K., Jensen T.S., Waxman S.G. Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann. Neurol. 2008;64:644–653. doi: 10.1002/ana.21527.
    1. Siqueira S.R., Alves B., Malpartida H.M., Teixeira M.J., Siqueira J.T. Abnormal expression of voltage-gated sodium channels Nav1.7, Nav1.3 and Nav1.8 in trigeminal neuralgia. Neuroscience. 2009;164:573–577. doi: 10.1016/j.neuroscience.2009.08.037.
    1. Kim D.W., Lee S.K., Ahnn J. Botulinum Toxin as a Pain Killer: Players and Actions in Antinociception. Toxins. 2015;7:2435–2453. doi: 10.3390/toxins7072435.
    1. Liampas A., Rekatsina M., Vadalouca A., Paladini A., Varrassi G., Zis P. Non-Pharmacological Management of Painful Peripheral Neuropathies: A Systematic Review. Adv. Ther. 2020;37:4096–4106. doi: 10.1007/s12325-020-01462-3.
    1. Couto D.S., Goulart G., Luciano L.L., Cardoso E.J.R. Quality of life in neuropathic pain: A literature review. Res. Soc. Dev. 2021;10:e416101422250. doi: 10.33448/rsd-v10i14.22250.
    1. Binder A., Baron R. The Pharmacological Therapy of Chronic Neuropathic Pain. Dtsch. Arztebl. Int. 2016;113:616–625. doi: 10.3238/arztebl.2016.0616.
    1. Higgins J.P., Thomas J., Chandler J., Cumpston M., Li T., Page M.J., Welch V.A., editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.2. John Wiley & Sons; Hoboken, NJ, USA: 2021.
    1. Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.
    1. Huang X., Lin J., Demner-Fushman D. Evaluation of PICO as a knowledge representation for clinical questions. AMIA Annu. Symp. Proc. 2006;2006:359–363.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir